QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)

Phreesia (PHR) Stock Forecast, Price & News

$32.28
-0.22 (-0.68%)
(As of 06/7/2023 ET)
Compare
Today's Range
$31.59
$33.08
50-Day Range
$28.01
$33.80
52-Week Range
$16.78
$40.00
Volume
343,630 shs
Average Volume
419,882 shs
Market Capitalization
$1.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.64

Phreesia MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
17.5% Upside
$37.92 Price Target
Short Interest
Bearish
5.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.04mentions of Phreesia in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$834,743 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.82) to ($2.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

323rd out of 981 stocks

Business Services, Not Elsewhere Classified Industry

51st out of 90 stocks


PHR stock logo

About Phreesia (NYSE:PHR) Stock

Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products. Its solutions include health systems, multi-specialty, and federally qualified health centers (FQHCs). The company was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in Wilmington, DE.

Receive PHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phreesia and its competitors with MarketBeat's FREE daily newsletter.

PHR Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Phreesia (NYSE:PHR) Stock Price Up 4.4% on Strong Earnings
Phreesia (NYSE:PHR) Price Target Cut to $40.00
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
JMP Securities Keeps Their Buy Rating on Phreesia (PHR)
Phreesia Announces First Quarter Fiscal 2024 Results
Phreesia: Q1 Earnings Insights
Phreesia Q1 2024 Earnings Preview
Earnings Preview: Phreesia
Phreesia (PHR) Scheduled to Post Earnings on Wednesday
See More Headlines

PHR Price History

PHR Company Calendar

Last Earnings
5/31/2023
Today
6/07/2023
Next Earnings (Estimated)
9/06/2023
Fiscal Year End
1/31/2024

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Employees
1,546
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.92
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+16.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-176,150,000.00
Pretax Margin
-53.71%

Debt

Sales & Book Value

Annual Sales
$280.91 million
Book Value
$4.92 per share

Miscellaneous

Free Float
50,477,000
Market Cap
$1.73 billion
Optionable
Not Optionable
Beta
0.62

Key Executives

  • Chaim IndigChaim Indig
    Chief Executive Officer & Director
  • Evan RobertsEvan Roberts
    Chief Operating Officer
  • Balaji Gandhi
    Chief Financial Officer
  • Daniel Nathan
    Chief Technology Officer
  • Russell Thatcher
    Vice President-Engineering













PHR Stock - Frequently Asked Questions

Should I buy or sell Phreesia stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PHR shares.
View PHR analyst ratings
or view top-rated stocks.

What is Phreesia's stock price forecast for 2023?

12 Wall Street analysts have issued 12 month price targets for Phreesia's shares. Their PHR share price forecasts range from $30.00 to $43.00. On average, they anticipate the company's stock price to reach $37.92 in the next year. This suggests a possible upside of 17.5% from the stock's current price.
View analysts price targets for PHR
or view top-rated stocks among Wall Street analysts.

How have PHR shares performed in 2023?

Phreesia's stock was trading at $32.36 at the beginning of 2023. Since then, PHR shares have decreased by 0.2% and is now trading at $32.28.
View the best growth stocks for 2023 here
.

When is Phreesia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 6th 2023.
View our PHR earnings forecast
.

How were Phreesia's earnings last quarter?

Phreesia, Inc. (NYSE:PHR) posted its quarterly earnings results on Wednesday, May, 31st. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.10. The firm had revenue of $83.85 million for the quarter, compared to analyst estimates of $80.64 million. Phreesia had a negative trailing twelve-month return on equity of 53.25% and a negative net margin of 53.89%. During the same period in the prior year, the business earned ($0.99) EPS.

What guidance has Phreesia issued on next quarter's earnings?

Phreesia updated its FY 2025 earnings guidance on Sunday, June, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.00 million-$500.00 million, compared to the consensus revenue estimate of $453.08 million.

What is Chaim Indig's approval rating as Phreesia's CEO?

172 employees have rated Phreesia Chief Executive Officer Chaim Indig on Glassdoor.com. Chaim Indig has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Phreesia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phreesia investors own include Fastly (FSLY), Zscaler (ZS), Okta (OKTA), DocuSign (DOCU), HealthEquity (HQY), Block (SQ), Appian (APPN), Walt Disney (DIS), Globant (GLOB) and Invitae (NVTA).

When did Phreesia IPO?

(PHR) raised $127 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 7,800,000 shares at $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray served as the underwriters for the IPO.

What is Phreesia's stock symbol?

Phreesia trades on the New York Stock Exchange (NYSE) under the ticker symbol "PHR."

Who are Phreesia's major shareholders?

Phreesia's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (13.34%), BlackRock Inc. (8.42%), Brown Advisory Inc. (6.05%), Credit Suisse AG (3.64%), Granahan Investment Management LLC (2.79%) and Jennison Associates LLC (2.58%). Insiders that own company stock include Allison C Hoffman, Allison C Hoffman, Amy Beth Vanduyn, Balaji Gandhi, Chaim Indig, Charles Kallenbach, Cheryl Pegus, Daniel Nathan, David Linetsky, Edward L Cahill, Edward L Cahill, Evan Roberts, Gillian Munson, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub, Randy Rasmussen and Thomas Altier.
View institutional ownership trends
.

How do I buy shares of Phreesia?

Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phreesia's stock price today?

One share of PHR stock can currently be purchased for approximately $32.28.

How much money does Phreesia make?

Phreesia (NYSE:PHR) has a market capitalization of $1.73 billion and generates $280.91 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($3.07) on an earnings per share basis.

How many employees does Phreesia have?

The company employs 1,546 workers across the globe.

How can I contact Phreesia?

Phreesia's mailing address is 432 Park Avenue South 12th Floor, New York NY, 10016. The official website for the company is www.phreesia.com. The company can be reached via phone at (888) 654-7473, via email at investors@phreesia.com, or via fax at 646-607-1776.

This page (NYSE:PHR) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -